Suppr超能文献

靶向 PET 检测犬的骨破坏性病变。

Pretargeted PET of Osteodestructive Lesions in Dogs.

机构信息

Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri 65211, United States.

Department of Chemistry, Hunter College, City University of New York, New York, New York 10065, United States.

出版信息

Mol Pharm. 2022 Sep 5;19(9):3153-3162. doi: 10.1021/acs.molpharmaceut.2c00220. Epub 2022 May 30.

Abstract

The last decade has witnessed the creation of a highly effective approach to pretargeting based on the inverse electron demand Diels-Alder (IEDDA) click ligation between tetrazine (Tz) and -cyclooctene (TCO). Despite the steady progression of this technology toward the clinic, concerns have persisted regarding whether this chemistry will work in humans given their larger size and blood volume. In this work, we describe the use of a Cu-labeled Tz radioligand ([Cu]Cu-SarAr-Tz) and a TCO-bearing bisphosphonate (TCO-BP) for the pretargeted positron emission tomography (PET) imaging of osteodestructive lesions in a large animal model: companion dogs. First, in a small animal pilot study, healthy mice were injected with TCO-BP followed after 1 or 6 h by [Cu]Cu-SarAr-Tz. PET images were collected 1, 6, and 24 h after the administration of [Cu]Cu-SarAr-Tz, revealing that this approach produced high activity concentrations in the bone (>20 and >15%ID/g in the femur and humerus, respectively, at 24 h post injection) as well as high target-to-background contrast. Subsequently, companion dogs ( = 5) presenting with osteodestructive lesions were administered TCO-BP (5 or 10 mg/kg) followed 1 h later by [Cu]Cu-SarAr-Tz (2.2-7.3 mCi; 81.4-270.1 MBq). PET scans were collected for each dog 4 h after the administration of the radioligand, and SUV values for the osteodestructive lesions, healthy bones, and kidneys were determined. In these animals, pretargeted PET clearly delineated healthy bone and produced very high activity concentrations in osteodestructive lesions. Low levels of uptake were observed in all healthy organs except for the kidneys and bladder due to the renal excretion of excess radioligand. Ultimately, this work not only illustrates that pretargeted PET with TCO-BP and [Cu]Cu-SarAr-Tz is an effective tool for the visualization of osteodestructive lesions but also demonstrates for the first time that pretargeting based on IEDDA click chemistry is feasible in large animals.

摘要

过去十年见证了一种基于逆电子需求 Diels-Alder(IEDDA)点击连接的前靶向方法的创建,该方法基于四嗪(Tz)和 -环辛烯(TCO)之间的反应。尽管该技术朝着临床应用稳步推进,但人们一直担心,鉴于人类的体型和血液量较大,这种化学物质是否会在人体中起作用。在这项工作中,我们描述了使用 Cu 标记的 Tz 放射性配体([Cu]Cu-SarAr-Tz)和带 TCO 的双膦酸盐(TCO-BP)对大型动物模型(伴侣犬)中的骨破坏性病变进行前靶向正电子发射断层扫描(PET)成像。首先,在一项小型动物初步研究中,健康小鼠注射 TCO-BP,1 或 6 小时后给予 [Cu]Cu-SarAr-Tz。在给予 [Cu]Cu-SarAr-Tz 后 1、6 和 24 小时采集 PET 图像,结果表明该方法在骨中产生了高活性浓度(股骨和肱骨分别在注射后 24 小时内超过 20 和 15%ID/g),并且具有高的靶标与背景对比度。随后,患有骨破坏性病变的伴侣犬(n=5)给予 TCO-BP(5 或 10 mg/kg),1 小时后给予 [Cu]Cu-SarAr-Tz(2.2-7.3 mCi;81.4-270.1 MBq)。对每只狗在给予放射性配体后 4 小时采集 PET 扫描,并确定骨破坏性病变、健康骨骼和肾脏的 SUV 值。在这些动物中,前靶向 PET 清晰地描绘了健康骨骼,并在骨破坏性病变中产生了非常高的活性浓度。除了肾脏和膀胱,由于过量放射性配体的肾排泄,所有健康器官的摄取水平都很低。最终,这项工作不仅说明了使用 TCO-BP 和 [Cu]Cu-SarAr-Tz 的前靶向 PET 是可视化骨破坏性病变的有效工具,而且还首次证明了基于 IEDDA 点击化学的前靶向在大型动物中是可行的。

相似文献

1
Pretargeted PET of Osteodestructive Lesions in Dogs.靶向 PET 检测犬的骨破坏性病变。
Mol Pharm. 2022 Sep 5;19(9):3153-3162. doi: 10.1021/acs.molpharmaceut.2c00220. Epub 2022 May 30.
3
Dual Radionuclide Theranostic Pretargeting.双重放射性核素治疗性靶向预定位。
Mol Pharm. 2019 Oct 7;16(10):4416-4421. doi: 10.1021/acs.molpharmaceut.9b00746. Epub 2019 Sep 9.
7
Harnessing Cu/Cu for a theranostic approach to pretargeted radioimmunotherapy.利用 Cu/Cu 实现前靶向放射性免疫治疗的治疗策略。
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28316-28327. doi: 10.1073/pnas.2009960117. Epub 2020 Oct 26.
9
Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate.使用位点特异性标记免疫偶联物的预靶向PET成像。
Bioconjug Chem. 2016 Aug 17;27(8):1789-95. doi: 10.1021/acs.bioconjchem.6b00235. Epub 2016 Jul 14.

引用本文的文献

2
Toward Realization of Bioorthogonal Chemistry in the Clinic.迈向临床生物正交化学的实现。
Top Curr Chem (Cham). 2025 Mar 5;383(2):12. doi: 10.1007/s41061-025-00495-y.
8
Click Chemistry and Radiochemistry: An Update.点击化学与放射化学:最新进展。
Bioconjug Chem. 2023 Nov 15;34(11):1925-1950. doi: 10.1021/acs.bioconjchem.3c00286. Epub 2023 Sep 22.
9
Click chemistry: a transformative technology in nuclear medicine.点击化学:核医学中的变革性技术。
Nat Protoc. 2023 Jun;18(6):1659-1668. doi: 10.1038/s41596-023-00825-8. Epub 2023 Apr 26.
10
Diagnostic and Therapeutic Radiopharmaceuticals.诊断与治疗用放射性药物
ACS Pharmacol Transl Sci. 2022 Sep 19;5(10):835-837. doi: 10.1021/acsptsci.2c00173. eCollection 2022 Oct 14.

本文引用的文献

6
Harnessing Cu/Cu for a theranostic approach to pretargeted radioimmunotherapy.利用 Cu/Cu 实现前靶向放射性免疫治疗的治疗策略。
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28316-28327. doi: 10.1073/pnas.2009960117. Epub 2020 Oct 26.
7
ImmunoPET: Concept, Design, and Applications.免疫正电子发射断层扫描:概念、设计与应用。
Chem Rev. 2020 Apr 22;120(8):3787-3851. doi: 10.1021/acs.chemrev.9b00738. Epub 2020 Mar 23.
10
Dual Radionuclide Theranostic Pretargeting.双重放射性核素治疗性靶向预定位。
Mol Pharm. 2019 Oct 7;16(10):4416-4421. doi: 10.1021/acs.molpharmaceut.9b00746. Epub 2019 Sep 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验